Particle size influences the immune response produced by hepatitis B vaccine formulated in lnhalable particles

Pharmaceutical Research

Volumn 27, Issue 5, 2010, Pages 905-919

  Thomas, Chandan ^a   Gupta, Vivek ^a   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bronchoalveolar lavage; Hepatitis b surface antigen; Immunogenicity; Microspheres; Pulmonary delivery

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; MICROSPHERE; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; POLYVINYL ALCOHOL; SOLVENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG UPTAKE; EMULSION; ENCAPSULATION; EVAPORATION; FEMALE; FLUORESCENCE ANALYSIS; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LUNG WEIGHT; MALE; NONHUMAN; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INHALATION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; EXCIPIENTS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, MUCOSAL; LACTIC ACID; LIPOSOMES; MACROPHAGES, ALVEOLAR; MICROSPHERES; PARTICLE SIZE; POLYGLYCOLIC ACID; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; VACCINES, SYNTHETIC;

EID: 77953286797     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0094-x     Document Type: Article

References (47)

1. Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, de Sousa A, Borchard G, et al. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release. 2006; 114: 348-358 (Pubitemid 44310817)
2. Zhou X, Liu B, Yu X, Zha X, Zhang X, Chen Y, et al. Controlled release of PEI/DNA complexes from mannose-bearing chitosan. microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine. J Control Release. 2007; 121:200-207 (Pubitemid 47214651)
3. O'Hagan DT, Rahman D, McGee JP, Jeffery H, Davies MC, Williams P, et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology. 1991; 73:239-4-12
4. Singh M, Kazzaz J, Ugozzoli M, Chesko J, O'Hagan. DT. Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin Biol Ther. 2004; 4:483-491 (Pubitemid 38480548)
5. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005; 57:391-410. (Pubitemid 39550967)
6. Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY, et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine. 1997; 15: 475-481
7. O'Hagan DT, McGee JP, Holmgren J, Mowat AM, Donachie AM, Mills KH, et al. Biodegradable microparticles for oral immunization. Vaccine. 1993; 11:149-154
8. Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine. 2006; 24:4201-4211
9. Bivas-Benita M, Ottenhoff TH, Junginger HE, Borchard G. Pulmonary DNA vaccination: concepts, possibilities and perspectives. J Control Release. 2005; 107:1-29.
10. Lu D, Hickey AJ. Pulmonary vaccine delivery. Expert Rev Vaccines. 2007; 6:213-226
11. Steinman RM. Some interfaces of dendritic cell biology. APMIS. 2003; 111:675-697
12. Zuckerman JN, Zuckerman AJ. Current topics in hepatitis B. J Infect. 2000; 41:130-136
13. Thomas C, Gupta V, Ahsan F. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm. 2009; 379:41-50.
14. Thomas C, Rawat A, Bai S, Ahsan F. Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside. J Pharm Sci. 2008; 97:1213-1223
15. Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vito and in vivo evaluation. J Control Release. 2008; 128:224-232
16. Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci. 2006; 28:423-432
17. Pandit S, Cevher E, Zariwala MG, Somavarapu S, Alpar HO. Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against hepatitis B through incorporation of alum and chitosan. J Microencapsul. 2007; 24:539-552
18. Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1, 2-dipaimitoylphosphatidylcholine. J Control Release. 1998; 51:143-152
19. Li M, Rouaud O, Poncelet D. Microencapsulation by solvent evaporation: state of the art for process engineering approaches. Int J Pharm. 2008; 363:26-39.
20. Reich G. Ultrasound-induced degradation of PLA and PLGA during microsphere processing: influence of formulation variables. Eur J Pharm Biopharm. 1998; 45:165-171
21. Sansdrap P, Moes AJ, Influence of manufacturing parameters on the size characteristcis and the release profiles of nifedipine from poly(DL-lactide-co- glycolide) microspheres. Int J Pharm. 1993; 98: 157-164
22. Scholes PD, Coombes AGA, Illum. L, Davis SS, Vert M, Davies MC, The preparation of sub-200 nm poly (lactide-co-glycolide) microspheres for site-specific drug delivery. J Control Release. 1993; 25:145-153
23. Yang YY, Chung TS, Ng NP. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials. 2001; 22:231-241
24. Crotts G, Park TG. Preparation of porous and nonporous biodegradable polymeric hollow microspheres. J Control Release. 1995; 35:91-105.
25. Igartua M, Hernandez RM, Esquisabel A, Gascon AR, Calvo MB, Pedraz JL. Stability of BSA encapsulated into PLGA microspheres using PAGE and capillary electrophoresis. Int J Pharm. 1998; 169:45-54.
26. Mao S, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int J Pharm, 2007; 334:137-148
27. Hussain A, Majumder QH, Ahsan F. Inhaled insulin is better absorbed when administered as a dry powder compared to solution, in the presence or absence of alkylglycosides. Pharm Res. 2006; 23:138-147
28. Xu H, Verbeken E, Vanhooren HM, Nemery B, Hoet PH. Pulmonary toxicity of polyvinyl chloride particles after a single intratracheal instillation in rats. Time course and comparison with silica. Toxicol Appl Pharmacol. 2004; 194:111-121
29. Toews GB. Cytokines and the lung. Eur Respir J Suppl. 2001; 34:3s-17.
30. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997; 276:1868-1871 (Pubitemid 27443665)
31. Amidi M, Pellikaan HC, Hirschberg H, de Boer AH, Crommelin DJ, Hennink WE, et al. Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine. 2007; 25:6818-6829
32. Amorij JP, Saluja V, Petersen AH, Hinrichs WL, Huckriede A, Frijlink HW. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine. 2007; 25:8707-8717
33. O'Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods (San Diego, Calif). 2006; 40:10-19
34. Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P, et al. Non-ionic surfactant based, vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm. 2005; 296:80-86
35. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 1991; 59:2978-2986
36. Jaganathan KS, Singh P, Prabakaran D, Mishra V, Vyas SP. Development of a single-dose stabilized poly(D, L-lactic-coglycolic acid) microspheres-based vaccine against hepatitis B. J Pharm Pharmacol. 2004; 56:1243-1250
37. Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK. Lipid microparticles for mucosal immunization against hepatitis B. Vaccine. 2006; 24:45-56. (Pubitemid 41722204)
38. O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine, 1993; 11:965-969
39. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release. 2006; 112:35-42.
40. Katare YK, Muthukumaran T, Panda AK, Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm. 2005; 301:149-160
41. Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004; 173:3148-3154
42. Brewer JM, Pollock KG, Tetley L, Russell DG. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J Immunol. 2004; 173:6143-6150
43. Kanke M, Sniecinski I, DeLuca PP. Interaction of microspheres with blood constituents: I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J Parenter Sci Technol. 1983; 37:210-217
44. Jain AK, Goyal AK, Gupta PN, Khatri K, Mishra N, Mehta A, et al. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B.J Control Release. 2009; 136:161-169
45. Lombry C, Marteleur A, Arras M, Lison D, Louahed J, Renauld JC, et al. Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice. Pharm Res. 2004; 21:127-135
46. Mishra D, Mishra PK, Dubey V, Nahar M, Dabadghao S, Jain NK. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigenloaded modified liposomes. Eur J Pharm Sci. 2008; 33:424-433
47. Oh YK, Park JS, Yoon H, Kim. CK. Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system. Vaccine. 2003; 21:1980-1988